The Asia Pacific Muscle Relaxant Drugs Market should witness market growth of 5.0% CAGR during the forecast period (2023-2029).
For people with spasticity who also have trouble swallowing tablets, the quickly dissolving flavored granules provide an option. The medication can be given to the patient in three different ways: straight into their mouths with or without water, while drinking or eating, or through an enteral feeding tube.
One of the main factors contributing to the rise in muscular weakness and musculoskeletal illnesses is the rising sedentary lifestyle and declining levels of activity, which is anticipated to drive the need for muscle relaxants throughout the forecasted period. For instance, research from around the world indicates that many adolescents do not engage in adequate physical activity. Furthermore, more than half of the population in economically developed nations is inactive.
Many medical professionals, especially rheumatologists, pain specialists, general practitioners, and mental health care professionals, have dealt with patients who report widespread chronic pain (pain all over the body), which is connected to several other symptoms like poor sleep, fatigue, and depression. Today, fibromyalgia (FM) is a diagnosis for this complicated combination of symptoms.
Osteoarthritis is the second most prevalent rheumatologic condition and the most prevalent joint disease in India, where its prevalence ranges from 22 to 38%. OA is more prevalent in women than in males, but the prevalence dramatically increases with age. Approximately 45% of women over 65 have symptoms, while 70% of those over 65 have radiological evidence. OA of the knee is a leading cause of mobility impairment, especially in women. It was estimated that osteoarthritis was the tenth leading cause of nonfatal burden. Thus, the high number of osteoarthritis cases will surge the demand for muscle relaxant drugs to ease the pain from such diseases, thereby driving the market's growth in the region.
The China market dominated the Asia Pacific Muscle Relaxant Drugs Market by Country in 2022 thereby, achieving a market value of $371.8 Million by 2029. The Japan market is registering a CAGR of 4.4% during (2023-2029). Additionally, The India market would showcase a CAGR of 5.6% during (2023-2029).
Based on Drug Type, the market is segmented into Skeletal, Neuromuscular Blocking Agents and Facial Muscle Relaxant Drugs. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amneal Pharmaceuticals, Inc., Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Mallinckrodt PLC, Teva Pharmaceuticals Industries Ltd., Eisai Co., Ltd., Endo International PLC, Vertical Pharmaceuticals, LLC, SteriMax Inc., and Metacel Pharmaceuticals, LLC.
For people with spasticity who also have trouble swallowing tablets, the quickly dissolving flavored granules provide an option. The medication can be given to the patient in three different ways: straight into their mouths with or without water, while drinking or eating, or through an enteral feeding tube.
One of the main factors contributing to the rise in muscular weakness and musculoskeletal illnesses is the rising sedentary lifestyle and declining levels of activity, which is anticipated to drive the need for muscle relaxants throughout the forecasted period. For instance, research from around the world indicates that many adolescents do not engage in adequate physical activity. Furthermore, more than half of the population in economically developed nations is inactive.
Many medical professionals, especially rheumatologists, pain specialists, general practitioners, and mental health care professionals, have dealt with patients who report widespread chronic pain (pain all over the body), which is connected to several other symptoms like poor sleep, fatigue, and depression. Today, fibromyalgia (FM) is a diagnosis for this complicated combination of symptoms.
Osteoarthritis is the second most prevalent rheumatologic condition and the most prevalent joint disease in India, where its prevalence ranges from 22 to 38%. OA is more prevalent in women than in males, but the prevalence dramatically increases with age. Approximately 45% of women over 65 have symptoms, while 70% of those over 65 have radiological evidence. OA of the knee is a leading cause of mobility impairment, especially in women. It was estimated that osteoarthritis was the tenth leading cause of nonfatal burden. Thus, the high number of osteoarthritis cases will surge the demand for muscle relaxant drugs to ease the pain from such diseases, thereby driving the market's growth in the region.
The China market dominated the Asia Pacific Muscle Relaxant Drugs Market by Country in 2022 thereby, achieving a market value of $371.8 Million by 2029. The Japan market is registering a CAGR of 4.4% during (2023-2029). Additionally, The India market would showcase a CAGR of 5.6% during (2023-2029).
Based on Drug Type, the market is segmented into Skeletal, Neuromuscular Blocking Agents and Facial Muscle Relaxant Drugs. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amneal Pharmaceuticals, Inc., Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Mallinckrodt PLC, Teva Pharmaceuticals Industries Ltd., Eisai Co., Ltd., Endo International PLC, Vertical Pharmaceuticals, LLC, SteriMax Inc., and Metacel Pharmaceuticals, LLC.
Scope of the Study
By Drug Type
- Skeletal
- Neuromuscular Blocking Agents
- Facial Muscle Relaxant Drugs
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Amneal Pharmaceuticals, Inc.
- Ipsen Pharma Biotech SAS
- Merz Pharma GmbH & Co. KGaA
- Mallinckrodt PLC
- Teva Pharmaceuticals Industries Ltd.
- Eisai Co., Ltd.
- Endo International PLC
- Vertical Pharmaceuticals, LLC
- SteriMax Inc.
- Metacel Pharmaceuticals, LLC
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Muscle Relaxant Drugs Market by Drug Type
Chapter 4. Asia Pacific Muscle Relaxant Drugs Market by Route of Administration
Chapter 5. Asia Pacific Muscle Relaxant Drugs Market by Distribution Channel
Chapter 6. Asia Pacific Muscle Relaxant Drugs Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Amneal Pharmaceuticals, Inc.
- Ipsen Pharma Biotech SAS
- Merz Pharma GmbH & Co. KGaA
- Mallinckrodt PLC
- Teva Pharmaceuticals Industries Ltd.
- Eisai Co., Ltd.
- Endo International PLC
- Vertical Pharmaceuticals, LLC
- SteriMax Inc.
- Metacel Pharmaceuticals, LLC
Methodology
LOADING...
